The World Health Organization and Eli Lilly and Co. are alerting the public about the dangers of fake weight-loss and diabetes medications. WHO has received reports of counterfeit semaglutide, an ingredient in Novo Nordisk’s popular drugs Wegovy and Ozempic, being sold worldwide since 2022. Lilly is suing multiple entities for falsely claiming to sell tirzepatide, the active ingredient in their diabetes medicines Mounjaro and Zepbound. The company warns against purchasing medications online or from unauthorized sources, emphasizing the risks involved with counterfeit drugs. Patients are advised to only obtain prescriptions from licensed physicians and to avoid unfamiliar sellers. Lilly stresses that any products marketed as tirzepatide and not Mounjaro or Zepbound are not approved or produced by them. With demand exceeding supply for GLP-1 drugs, caution is urged when purchasing these medications to ensure safety and authenticity.